AU-314 is under clinical development by Aucentra Therapeutics and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase II drugs for Pancreatic Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AU-314’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AU-314 is under development for the treatment of solid tumors including metastatic brain tumor, high grade glioma, recurrent glioblastoma multiforme, cervical, colon, pancreatic and uterine cancers, lung cancer, ovarian, colorectal, liver and breast cancer. It is administered through oral route in the form of capsule. It targets cyclin dependent kinase 4 and 6 (CDK4 and CDK6).
Aucentra Therapeutics overview
Aucentra Therapeutics is an Australian developer of targeted cancer therapeutics. It carries out pre-clinical drug development, drug discovery and research and development activities.
For a complete picture of AU-314’s drug-specific PTSR and LoA scores, buy the report here.